INVITATION
Mastitis Symposium
September 20th, Ghent University

Update on hot topics and results of mastitis vaccination

- Paolo Moroni
- Sarne De Vliegher
- Sofie Piepers
- Valerio Bronzo
- Andrew Bradley
UPDATE ON HOT TOPICS AND RESULTS OF MASTITIS VACCINATION
Thursday, September 20th • 14:00h - 18:00h
Kliniekauditorium A, Faculty of Veterinary Medicine
Ghent University, Salisburylaan 133 • B-9820 Merelbeke

Welcome
RENS DEFRENNE, Product Manager HIPRA Benelux.

Biofilm concept
PAOLO MORONI, Quality Milk Production Services (QMPS), Animal Health Diagnostic Center, Cornell University, USA.

Coagulate-negative staphylococci: an intriguing group of bacteria involved in mastitis
SARNE DE VLIEGHER, Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, Belgium. Chairman.

Immunological approach to S. aureus infections
SOFIE PIEPERS, Department of Reproduction, Obstetrics and Herd Health, Faculty of Veterinary Medicine, Ghent University, Belgium.

Coffee break

STARTVAC®, new tool to control S. aureus Mastitis
VALERIO BRONZO, Department of Health, Animal Science and Food Safety, School of Veterinary Medicine, Università degli Studi di Milano, Italy.

Management of coliform Mastitis
ANDREW BRADLEY, Clinical Reader in Dairy Production Medicine, School of Veterinary Medicine and Science, University of Nottingham, UK

Discussion

Walking Dinner

STARTVAC® Inactivated vaccine, Bovine mastitis, in injectable emulsion. COMPOSITION PER DOSE (2 ML): inactivated Escherichia coli (J5) 50 RED60*; inactivated Staphylococcus aureus (CP8) 140 strain expressing SAAC** 50 RED80***. Adjuvant. * RED60: Rabbit effective dose in 60% of the animals (serology). **SAAC: Slime Associated Antigenic Complex. ***RED80: Rabbit effective dose in 80% of the animals (serology). PROPERTIES: Mastitis is one of the main problems in dairy cows, not only from an economic point of view due to losses in the quantity and quality of the milk, but also from a sanitary point of view, because the milk produced has low bacteriological quality and a high level of antibiotics, as a consequence of antimastitis treatments. The vaccine STARTVAC, which combines specific antigens and a special adjuvant, prevents and reminits the effects of mastitis caused by Staphylococcus aureus (the main responsible for chronic mastitis) and Escherichia coli (causative agent of acute clinical mastitis). INDICATIONS: Cows and Heifers: to prevent Mastitis. For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of subclinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by Staphylococcus aureus, coliforms and coagulate-negative staphylococci. The full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days post-parturition). SIDE EFFECTS: Slight to moderate transient local reactions may occur after the administration of one dose of vaccine, which disappears within 1 or 2 weeks at most. ADMINISTRATION ROUTE: Intramuscular into the neck muscles. The injections should be preferably administered on the alternate sides of the neck. It is advisable to administer the vaccine at a temperature between +15 and +25 ºC. Shake before use. DOSAGE: Cows and Heifers: 2 ml/animal. Generally, the following vaccination programme is recommended: First injection: at 45 days before the expected parturition date. Second injection: 35 days thereafter (corresponding to 10 days the expected parturition date). Third injection: 62 days after the second injection (equivalent to 52 days post-parturition). The full immunisation programme should be repeated with each gestation. The whole herd should be immunised. Immunisation has to be considered as one component in a complex mastitis control program that addresses all important udder health factors (e.g. milking technique, dry-off and breeding management, hygiene, nutrition, bedding, cow comfort, air and water quality, health monitoring) and other management practices. Can be used during pregnancy and lactation. WITHDRAWAL PERIOD: 0 days. SPECIAL PRECAUTIONS: Store at +2 to +8 ºC, avoiding freezing. Protect from light. PACKAGING: Pack of 20 vials of 1 ds. 5 ds vial. 25 ds bottle. Under veterinary prescription. Marketing authorization holder: Laboratorios Hipra, S.A. la Selva, 135, 17170-AMER (Girona) SPAIN. Legal category: UK: POM-V . ROI: POM . Marketing authorisation numbers: 1 dose: EU/2/08/092/003; 5 doses: EU/2/08/092/004; 25 doses: 2/08/092/006. Use medicines responsibly.